Lu Yang

2.8k total citations
98 papers, 2.0k citations indexed

About

Lu Yang is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Lu Yang has authored 98 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 59 papers in Oncology, 53 papers in Pulmonary and Respiratory Medicine and 23 papers in Molecular Biology. Recurrent topics in Lu Yang's work include Lung Cancer Treatments and Mutations (46 papers), Lung Cancer Research Studies (26 papers) and Colorectal Cancer Treatments and Studies (14 papers). Lu Yang is often cited by papers focused on Lung Cancer Treatments and Mutations (46 papers), Lung Cancer Research Studies (26 papers) and Colorectal Cancer Treatments and Studies (14 papers). Lu Yang collaborates with scholars based in China, United States and Ethiopia. Lu Yang's co-authors include Jie Wang, Hua Bai, Yan Wang, Tongtong An, Jun Zhao, Jinhua Xu, Minglei Zhuo, Yanhong Shou, Jianchun Duan and Yuyan Wang and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Lu Yang

88 papers receiving 2.0k citations

Peers

Lu Yang

PRM

ONCOL

IMMUN

David Garfield United States

Lorena Incorvaia Italy

Atsushi Horiike Japan

Elaine T. Lam United States

Harold Keer United States

Hideki Kimura Japan

Nicola Battelli Italy

G. Deplanque France

Eiki Ichihara Japan

Ryan J. Hartmaier United States

David Garfield United States

Lu Yang

1.2k ×1.0

PRM

1.1k ×1.0

ONCOL

622 ×0.9

769 ×1.2

235 ×1.1

IMMUN

Citations per year, relative to Lu Yang Lu Yang (= 1×) peers David Garfield

Countries citing papers authored by Lu Yang

Since Specialization

Citations

This map shows the geographic impact of Lu Yang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lu Yang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lu Yang more than expected).

Fields of papers citing papers by Lu Yang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lu Yang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lu Yang. The network helps show where Lu Yang may publish in the future.

Co-authorship network of co-authors of Lu Yang

This figure shows the co-authorship network connecting the top 25 collaborators of Lu Yang. A scholar is included among the top collaborators of Lu Yang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lu Yang. Lu Yang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wang, L.G., et al.. (2025). Efficient Photocatalytic Degradation of Tetracycline Over a Novel Dual Z-Scheme Bi₂O₃/ZnTiO₃–SrTiO₃ Composite Photocatalyst. Langmuir. 41(9). 5848–5859.

Chen, Ying, et al.. (2025). Therapeutic effects of Melittin acupoint injection on rheumatoid arthritis through autophagy activation and PI3K/AKT/mTOR pathway inhibition. Quantitative Imaging in Medicine and Surgery. 16(1). 18–18.

Zhang, Shiyu, Lu Yang, Lu Lu, et al.. (2025). Proteomic analysis of plasma and urine for efficacy prediction biomarkers of Janus kinase inhibitors combined with phototherapy in vitiligo. British Journal of Dermatology. 192(6). 1141–1143.

Yang, Lu, et al.. (2024). CLIP-Guided Federated Learning on Heterogeneity and Long-Tailed Data. Proceedings of the AAAI Conference on Artificial Intelligence. 38(13). 14955–14963. 11 indexed citations

Li, Qi, Zhipeng Wang, Shiying Yang, et al.. (2024). New Co-Crystals of Betaine: Significant Improvements in Hygroscopicity. Crystals. 14(11). 917–917. 1 indexed citations

Yue, Tao, Baoxi Zhang, Li Zhang, et al.. (2024). New Cocrystals of Ligustrazine: Enhancing Hygroscopicity and Stability. Molecules. 29(10). 2208–2208. 9 indexed citations

Dai, Xiaoxia, et al.. (2024). Identification of fibrosis-associated lncRNAs in diabetic cardiomyopathy patients. Endokrynologia Polska. 75(5). 525–538.

Liu, Li, Jingsi Dong, Puyuan Xing, et al.. (2023). 2025P Stratified control study of neuroendocrine differentiation and potential clinicopathologic markers. Annals of Oncology. 34. S1075–S1075. 1 indexed citations

Yang, Lu, Yaning Yang, Guangjian Yang, et al.. (2023). The efficacy and safety of chemo‐free therapy in epidermal growth factor receptor tyrosine kinase inhibitor‐resistant advanced non‐small cell lung cancer: A single‐arm, phase II study. Cancer Medicine. 12(19). 19438–19448. 3 indexed citations

10.

Liu, Chengming, Lu Yang, Haiyan Xu, et al.. (2022). Systematic analysis of IL-6 as a predictive biomarker and desensitizer of immunotherapy responses in patients with non-small cell lung cancer. BMC Medicine. 20(1). 187–187. 55 indexed citations

11.

Liu, Chengming, Sufei Zheng, Zhanyu Wang, et al.. (2022). KRAS ‐G12D mutation drives immune suppression and the primary resistance of anti‐PD‐1/PD‐L1 immunotherapy in non‐small cell lung cancer. Cancer Communications. 42(9). 828–847. 99 indexed citations

12.

Sun, Hengwen, et al.. (2022). Comparisons of Metastatic Patterns, Survival Outcomes and Tumor Immune Microenvironment Between Young and Non-Young Breast Cancer Patients. Frontiers in Cell and Developmental Biology. 10. 923371–923371. 11 indexed citations

13.

Yang, Yaning, Haiyan Xu, Li Ma, et al.. (2021). Possibility of brigatinib‐based therapy, or chemotherapy plus anti‐angiogenic treatment after resistance of osimertinib harboring EGFR T790M‐cis‐C797S mutations in lung adenocarcinoma patients. Cancer Medicine. 10(23). 8328–8337. 11 indexed citations

14.

Yang, Guangjian, Jun Li, Haiyan Xu, et al.. (2020). EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world study. Lung Cancer. 145. 186–194. 75 indexed citations

15.

Yang, Lu, Sheng Yang, Yutao Liu, et al.. (2018). Combination TS‐1 plus EGFR‐tyrosine kinase inhibitors (TKIs) for the treatment of non‐small cell lung cancer after progression on first‐line or further EGFR‐TKIs: A phase II, single‐arm trial. Thoracic Cancer. 9(6). 693–698. 4 indexed citations

16.

Zhou, Qing, Yong Song, Xin Zhang, et al.. (2017). A multicenter survey of first-line treatment patterns and gene aberration test status of patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer in China (CTONG 1506). BMC Cancer. 17(1). 462–462. 23 indexed citations

17.

Bai, Hua, Zhijie Wang, Yuyan Wang, et al.. (2013). Detection and Clinical Significance of Intratumoral EGFR Mutational Heterogeneity in Chinese Patients with Advanced Non-Small Cell Lung Cancer. PLoS ONE. 8(2). e54170–e54170. 83 indexed citations

18.

Wang, Zhijie, Tony Mok, Lu Yang, et al.. (2011). Immediate versus delayed treatment with EGFR tyrosine kinase inhibitors after first-line therapy in advanced non-small-cell lung cancer. Chinese Journal of Cancer Research. 23(2). 112–117. 1 indexed citations

19.

Kralik, Patricia M., Ye Song, Lu Yang, et al.. (2009). Diabetic Albuminuria Is Due to a Small Fraction of Nephrons Distinguished by Albumin-Stained Tubules and Glomerular Adhesions. American Journal Of Pathology. 175(2). 500–509. 16 indexed citations

20.

Chen, Fengsheng, Xi Luo, Jinbiao Zhang, Lu Yang, & Rongcheng Luo. (2009). Elevated serum levels of TPS and CYFRA 21-1 predict poor prognosis in advanced non-small-cell lung cancer patients treated with gefitinib. Medical Oncology. 27(3). 950–957. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact